Furthermore, the synergistic anti-tumour effect of PD-1/PD-L1 inhibitors plus anti-angiogenic agents is also evident in other solid tumours, such as gastric or oesophagogastric junction cancer patients.38 Collectively, future combinational strategies based on PD-1/-DL1 antibodies in ED-SCLC could be relevant and of clinical interest. The gene discussed is DLL1; the disease is neoplasm.